Literature DB >> 10613822

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

B Jiménez1, O V Volpert, S E Crawford, M Febbraio, R L Silverstein, N Bouck.   

Abstract

Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that limits vessel density in normal tissues and curtails tumor growth. Here, we show that the inhibition of angiogenesis in vitro and in vivo and the induction of apoptosis by thrombospondin-1 all required the sequential activation of CD36, p59fyn, caspase-3 like proteases and p38 mitogen-activated protein kinases. We also detected increased endothelial cell apoptosis in situ at the margins of tumors in mice treated with thrombospondin-1. These results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613822     DOI: 10.1038/71517

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  311 in total

Review 1.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

4.  Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36.

Authors:  Yuben Moodley; Paul Rigby; Chris Bundell; Stuart Bunt; Hideyuki Hayashi; Neil Misso; Robin McAnulty; Geoffrey Laurent; Amelia Scaffidi; Philip Thompson; Darryl Knight
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

5.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

6.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

7.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

8.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

Authors:  Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

Review 9.  Angiogenesis as a target in rheumatoid arthritis.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

10.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.